These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 21568893)

  • 1. Pharmacophore modelling: a forty year old approach and its modern synergies.
    Caporuscio F; Tafi A
    Curr Med Chem; 2011; 18(17):2543-53. PubMed ID: 21568893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploration of the structural requirements of HIV-protease inhibitors using pharmacophore, virtual screening and molecular docking approaches for lead identification.
    Islam MA; Pillay TS
    J Mol Graph Model; 2015 Mar; 56():20-30. PubMed ID: 25541527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacophore based drug design approach as a practical process in drug discovery.
    Gao Q; Yang L; Zhu Y
    Curr Comput Aided Drug Des; 2010 Mar; 6(1):37-49. PubMed ID: 20370694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacophore modeling and applications in drug discovery: challenges and recent advances.
    Yang SY
    Drug Discov Today; 2010 Jun; 15(11-12):444-50. PubMed ID: 20362693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receptor-based pharmacophore tool for design and development of next-generation drugs.
    Udayakumar M; Kumar PS; Hemavathi K; Shanmugapriya P; Seenivasagam R
    Int J Bioinform Res Appl; 2013; 9(5):487-516. PubMed ID: 24001724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of Novel Potential gp120 of HIV-1 Antagonist Using Per-Residue Energy Contribution-Based Pharmacophore modelling.
    Berinyuy E; Soliman MES
    Interdiscip Sci; 2017 Sep; 9(3):406-418. PubMed ID: 27165479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New features that improve the pharmacophore tools from Accelrys.
    Sutter J; Li J; Maynard AJ; Goupil A; Luu T; Nadassy K
    Curr Comput Aided Drug Des; 2011 Sep; 7(3):173-80. PubMed ID: 21726193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation.
    Halder AK; Saha A; Saha KD; Jha T
    J Biomol Struct Dyn; 2015; 33(8):1756-79. PubMed ID: 25350685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Computational Evaluation of HIV-1 gp120 Conformations of Soluble Trimeric gp140 Structures as Targets for de Novo Docking of First- and Second-Generation Small-Molecule CD4 Mimics.
    Moraca F; Acharya K; Melillo B; Smith AB; Chaiken I; Abrams CF
    J Chem Inf Model; 2016 Oct; 56(10):2069-2079. PubMed ID: 27602436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Development of Pharmacophore Modeling: Generation and Recent Applications in Drug Discovery.
    Lu X; Yang H; Chen Y; Li Q; He SY; Jiang X; Feng F; Qu W; Sun H
    Curr Pharm Des; 2018; 24(29):3424-3439. PubMed ID: 30101699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of novel inhibitors of Mycobacterium tuberculosis MurG: homology modelling, structure based pharmacophore, molecular docking, and molecular dynamics simulations.
    Saxena S; Abdullah M; Sriram D; Guruprasad L
    J Biomol Struct Dyn; 2018 Sep; 36(12):3184-3198. PubMed ID: 28948866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Exploration of New and Potent Lead Molecules Against CAAX Prenyl Protease I of Leishmania donovani Through Pharmacophore Based Virtual Screening Approach.
    Prabhu SV; Tiwari K; Suryanarayanan V; Dubey VK; Singh SK
    Comb Chem High Throughput Screen; 2017; 20(3):255-271. PubMed ID: 28116998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacophore-based virtual screening.
    Horvath D
    Methods Mol Biol; 2011; 672():261-98. PubMed ID: 20838973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel Transforming Growth Factor-Beta Receptor 1 Antagonists through a Pharmacophore-Based Virtual Screening Approach.
    Jiang J; Zhou H; Jiang Q; Sun L; Deng P
    Molecules; 2018 Oct; 23(11):. PubMed ID: 30384428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pseudoreceptor models in drug design: bridging ligand- and receptor-based virtual screening.
    Tanrikulu Y; Schneider G
    Nat Rev Drug Discov; 2008 Aug; 7(8):667-77. PubMed ID: 18636071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrated ligand based pharmacophore model derived from diverse FAAH covalent ligand classes.
    Shen L; Huang H; Makriyannis A; Fisher LS
    Curr Comput Aided Drug Des; 2012 Dec; 8(4):330-4. PubMed ID: 22734710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First universal pharmacophore model for hERG1 K
    Durdagi S; Erol I; Salmas RE; Patterson M; Noskov SY
    J Mol Graph Model; 2017 Jun; 74():153-170. PubMed ID: 28499268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacophore generation, atom-based 3D-QSAR, molecular docking and molecular dynamics simulation studies on benzamide analogues as FtsZ inhibitors.
    Tripathy S; Azam MA; Jupudi S; Sahu SK
    J Biomol Struct Dyn; 2018 Sep; 36(12):3218-3230. PubMed ID: 28938860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico modelling and molecular dynamics simulation studies of thiazolidine based PTP1B inhibitors.
    Mahapatra MK; Bera K; Singh DV; Kumar R; Kumar M
    J Biomol Struct Dyn; 2018 Apr; 36(5):1195-1211. PubMed ID: 28393626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deterministic pharmacophore detection via multiple flexible alignment of drug-like molecules.
    Schneidman-Duhovny D; Dror O; Inbar Y; Nussinov R; Wolfson HJ
    J Comput Biol; 2008 Sep; 15(7):737-54. PubMed ID: 18662104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.